Rapamycin: How the Longevity Drug Affects Exercise

A clinical trial has revealed that the “longevity drug” rapamycin may not enhance the benefits of exercise in older adults, and could potentially blunt them. The randomized, double-blind, placebo-controlled trial, dubbed RAPA-EX-01, was published on April 15, 2026, in the Journal of Cachexia, Sarcopenia and Muscle.

Researchers investigated whether alternating activation and inhibition of mechanistic target of rapamycin complex 1 (mTORC1) – a process known as the ‘cycling hypothesis’ – could enhance adaptation to exercise. However, the study found no evidence to support this theory. The trial involved older adults and examined the effects of weekly sirolimus (rapamycin) alongside exercise.

Study Details and Methodology

The RAPA-EX-01 trial was conducted by researchers from the Royal New Zealand College of General Practitioners, the University of Auckland, the University of Washington, Optispan Inc., and BioValeo. Brad Stanfield of the Royal New Zealand College of General Practitioners and the University of Auckland served as the lead author. The study was revised on February 10, 2026, after initial receipt on November 23, 2025, and accepted for publication on February 27, 2026. Data collection concluded in April 2026.

The study design involved a randomized, double-blind, placebo-controlled approach, considered a gold standard in clinical research. This methodology helps minimize bias and ensures the reliability of the findings. Participants were randomly assigned to receive either sirolimus (rapamycin) or a placebo, in addition to engaging in an exercise program.

Rapamycin and mTORC1: The ‘Cycling Hypothesis’

Rapamycin is an immunosuppressant drug that has gained attention for its potential anti-aging properties. It works by inhibiting mTORC1, a protein complex that plays a crucial role in cell growth, proliferation, and survival. Preclinical studies have suggested that intermittent inhibition of mTORC1, combined with the activation induced by exercise, could lead to enhanced muscle adaptation and overall health benefits – the ‘cycling hypothesis.’

The rationale behind the ‘cycling hypothesis’ is that temporarily suppressing mTORC1 allows cells to enter a state of autophagy, a process where they clear out damaged components. When mTORC1 is then reactivated through exercise, the cells can rebuild with improved efficiency, and resilience.

Study Findings and Implications

Contrary to the ‘cycling hypothesis,’ the RAPA-EX-01 trial did not demonstrate that weekly sirolimus enhanced the adaptive response to exercise in older adults. The study’s abstract, published in the Journal of Cachexia, Sarcopenia and Muscle, indicates that the drug did not provide the anticipated benefits. Further details regarding specific outcomes and statistical significance are not yet available in publicly accessible summaries.

These findings suggest that the benefits of rapamycin observed in preclinical models may not translate directly to humans, or that the optimal dosing and timing of rapamycin administration may differ. The results also highlight the complexity of translating laboratory findings to clinical practice.

Future Research and Considerations

The researchers emphasize the need for further investigation to fully understand the effects of rapamycin on exercise adaptation in older adults. Future studies could explore different dosages, frequencies of administration, and combinations with various exercise modalities. We see also important to consider individual variability in response to rapamycin, as genetic factors and pre-existing health conditions may influence its effects.

Brad Stanfield, the corresponding author of the study, can be reached at brad@drstanfield.com. The study was funded by Dr Brad Stanfield Ltd. And published under an open access license, allowing for widespread use, distribution, and reproduction with proper citation.